Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Podsumowanie

Here, we present a protocol for the intra-cardiac injection of human prostate cancer cells to generate a mouse model with bone metastasis lesions.

Streszczenie

As the most common male malignancy, prostate cancer (PC) ranks second in mortality, primarily due to a 65%-75% bone metastasis rate. Therefore, it is essential to understand the process and related mechanisms of prostate cancer bone metastasis for developing new therapeutics. For this, an animal model of bone metastasis is an essential tool. Here, we report detailed procedures to generate a bone metastasis mouse model via intra-cardiac injection of prostate cancer cells. A bioluminescence imaging system can determine whether prostate cancer cells have been accurately injected into the heart and monitor cancer cell metastasis since it has great advantages in monitoring metastatic lesion development. This model replicates the natural development of disseminated cancer cells to form micro-metastases in the bone and imitates the pathological process of prostate cancer bone metastasis. It provides an effective tool for further exploration of the molecular mechanisms and the in vivo therapeutic effects of this disease.

Wprowadzenie

Prostate cancer is the most frequent cancer in men in 112 countries and ranks second for mortality in higher human development index countries^1,2. Most deaths in prostate cancer patients are caused by metastasis, and about 65%-75% of the cases will develop bone metastasis^3,4. Therefore, prevention and treatment of prostate cancer bone metastases are urgently needed to improve the clinical outcome of prostate cancer patients. The animal model of bone metastasis is an indispensable tool for exploring the multistage process and molecular mechanisms involved in each stage of prostate cancer bone metastasis, thus identifying therapeutic targets and developing novel therapeutics⁵.

The most common methods to generate experimental animal models of prostate cancer bone metastasis include the orthotopic, intra-diaphysis (such as intra-tibial), and intra-cardiac injection of prostate cancer cells. The bone metastasis model with orthotopic injection is generated by directly injecting prostate cancer cells into the prostate of a mouse^6,7. This experimental animal model has very similar clinical characteristics to prostate cancer bone metastasis. However, the metastasis mainly happens in the axillary lymph node and the lung rather than in the bone^8,9.The intra-tibial injection model for prostate cancer directly injects prostate cancer cells into the tibia with a hightumor formation rate in the bone (tibia)^10,11; however, the bone cortex and bone marrow cavity are easily damaged. Additionally, the tibial injection method cannot stimulate the pathological process of prostate cancer bone metastasis in which the cancer cells colonize the bone through circulation. To investigate the circulation, vascular extravasation, and distant metastasis with a higher bone metastasis rate of cancer cells, an intra-cardiac injection technique has been developed by directly injecting prostate cancer cells into the left ventricle of the mouse^8,12,13. This makes it a valuable animal model for bone metastasis research⁸. The intra-cardiac injection method shows a bone metastasis rate of about 75%^9,14, much higher than the orthotopic injection method. Therefore, the intra-cardiac injection is an ideal method to generate an animal model with prostate cancer bone metastasis.

This work aims to describe the process of establishing a mouse model of prostate cancer bone metastases, allowing readers to visualize the model establishment. The current work provides detailed processes, precautions, and illustrative pictures to generate a bone metastasis xenograft model via intra-cardiac injection of human prostate cancer cells in athymic mice. This method provides an effective tool for further exploring the molecular mechanisms and the in vivo therapeutic effects of prostate cancer bone metastasis.

Protokół

Six to eight week old male BALB/c athymic mice (n = 10) were housedin individually ventilated mice cages (5 mice/cage) in a specific-pathogen-free (SPF) animal room under the conditions of 12 h light/dark cycle, with free access to SPF feed and sterile water. Mice were adaptively fed for a week before the experiments.All animal experiments were approved by the animal welfare committee of Shanghai University of Traditional Chinese Medicine.

1. Cell preparation

1. On the day of prostate cancer cell injection, wash 80%-90% confluent luciferase labeled PC-3 cells (PC-3-luciferase) cultured in a 10 cm cell culture dish with pre-cold sterile PBS (pH 7.4) twice. Trypsinize for 3 min with 1.5 mL of 0.25% trypsin, and collect the cells into a 15 mL centrifuge tube after quenching the trypsin with 6 mL of F-12 medium containing 10% serum.
   NOTE: The PC-3-luciferase cell line is derived from the PC-3 cell line after being transfected with the pLV-luciferase vector¹⁵.
2. Use an automatic cell counter and calculate the cell concentration by transferring 20 µL of the cell suspension to the cell counting plate (see Table of Materials).
3. Centrifuge the cells at 800 x g at room temperature (RT) for 5 min.
4. Use a pipette to discard the supernatant and resuspend the cell pellet in F-12 medium (see Table of Materials) to a final cell density of 1 x 10⁷ cells/mL.
5. Keep the cells on ice at all times until injection.
6. Bring the cells to the surgery room and finish the cell injection within 2 h.
   NOTE: Prepare additional cell suspensions (usually doubled volumes as required) to ensure accurate injection doses (for example, to avoid the dead spaces inside the syringes).

2. Surgery for intra-cardiac injection of the human prostate cancer cells

NOTE: The surgical apparatus used for intra-cardiac injection is a 1 mL syringe (Figure 1). Provide thermal support throughout the procedure until the animal’s recovery from anesthesia.

1. Keep the mouse in the SPF animal room. Perform all the procedures with sterilized apparatuses within an aseptic cabinet.
2. Anesthetize the mouse using 2% isoflurane with 98% oxygen under a 2 L/min oxygen flow rate.
   NOTE: Smear a small quantity of ophthalmic ointment on the mouse's eyes to avoid dryness during the anesthesia.Perform the whole surgery in a well-ventilated area. Make sure that the mouse is deeply anesthetized by pinching the mouse's toes before cell injection. If responses (e.g., a jerk or twitch) remain, wait for additional time for the anesthesia to take effect.
3. Place the mouse in a supone position and immobilize both upper limbs perpendicularly stretched away from the midline (Figure 2A).
4. Immobilize the mouse from the abdomen down with surgical adhesive tape. Avoid pressing hard and displacing the internal organs (Figure 2B).
   NOTE: Maintaining the topographic anatomy (i.e., fixing with adhesive tape) is essential since the intra-cardiac injection is blind (i.e., the accurate injection site on the heart is invisible to the naked eye).
5. Disinfect the skin of the thorax with a 70% ethanol swab.
6. Identify the mouse xiphoid process in the depression at the lowest end of the mid-sternum by palpating down the middle of the anterior chest wall. Identify the mouse jugular notch in the central depression at the upper border of the manubrium by palpating up from the middle of the anterior chest wall.
7. Label the most inferior point of the xiphoid process and jugular notch with a marker pen (Figure 2A). Make a third mark in the middle of these two landmarks and slightly to the right (animal's left) just over the heart in the third intercostal space.
   NOTE: The site of injection is 1-2 mm left of the midline, and the injection point is between the third and fourth ribs of the mouse (Figure 2A).
8. Load 200 µL of the cell suspension into a 1 mL syringe.
   NOTE: Keep an air bubble in the syringe, as shown in Figure 2C, to ensure that the blood is pulsating. The cell suspension must be thoroughly mixed before loading.
9. Vertically insert a 26 G needle through the injection site (Figure 2D).
10. Keep the hand holding the syringe stable on the table, or use the other hand to hold it stable. Ensure that the long axis of the syringe is perpendicular to the injection site, and insert the syringe about 2 mm subcutaneously.
11. Bright-red blood pulsation is visible in the needle hub and/or cell suspension when the needle tip is correctly inserted into the left ventricle. If the blood pulsation is invisible, the needle tip is not in the heart. Retract and replace the needle (in case the blood clotting inside the needle stops blood pulsation). Insert the needle once again.
12. Inject the cells. Inject the cell suspension (100 µL) very slowly over 40-60 s and keep the hand holding the syringe stable all the time.
    NOTE: Keep a close eye on the cell suspension in the syringe, and do not inject the air bubble inside the syringe into the heart.
13. Apply pressure to the injection site with a dry cotton swab for 15 s to ensure hemostasis when the needle is retracted.
14. Return the mouse to the clean cage and monitor the animal until it completely recovers from anesthesia.
15. Image the mouse with an in vivo bioluminescence system within 24 h post-injection to ensure the cancer cells have entered the systemic circulation.
    NOTE: Correctly injected cancer cells enter the arterial circulation via the left heart ventricle, which is seen by the bioluminescence signaling visible all over the body (for example, see Figure 3A).
16. Perform in vivo bioluminescence imaging.
    1. Turn on the instrument and the computer. Open the software when the power indicator on the instrument and computer brightens, and then open the Image Acquisition window.
    2. Identify the in vivo imaging system connected to the computer in the device pane. Place the mouse to be imaged into the imaging chamber in a supine position. Then close the door of the imaging chamber.
    3. Set the parameters on the Setting pane provided in the Image Acquisition window.
       1. Set the parameters with Lens > Zoom > 1x, Lens > Focus > 108, and Lens > Iris > F 2.8 to make the images clear.
       2. Set the shooting channel in Filter&Light: Filter&Light > Filter > Luminescence, Filter&Light > Light > OFF, and Filter&Light > Light Intensity > Middle.
       3. Set the type of image to be taken: Imaging > Type > Single-Frame, Imaging > Exposure Time > 500 ms, Imaging > HDR Mode > Low GainMode. Click on the Acquire button to acquire the image.
17. Visualize the metastatic cancer growth with in vivo bioluminescence.
    NOTE: At each time point of the visualization, intraperitoneally inject 200 µL of the luciferin substrate into a 20 g mouse (150 mg/kg) and wait 15 min before the anesthesia (2% isoflurane mixed with 98% oxygen in an induction chamber). Place the mouse on the bioluminescence imaging system platform. Maintain anesthesia through a nasal mask with 2% isoflurane.

3. Pathologic investigation

1. Four weeks after the cell injection, sacrifice the mouse by CO₂ inhalation and then cervical dislocation.
2. Immobilize the mouse in a supine position. Make a vertical incision (about 6 cm) from the abdomen to the thorax with surgical scissors to expose and grossly examine all the organs in the abdomen and thorax for cancerous lesions and/or pathological changes.
   NOTE: For an intra-cardiac cancer cell injection study, cancer lesions in the mediastinum adjacent to the heart suggest misinjected cancer cells (cells not injected into the left cardiac ventricle); therefore, these mice are not included in the final data collection.
3. Excise the metastatic tumors with scissors. Measure the long diameters (a) and short diameters (b) of the tumor using calipers to calculate the tumor volume (V) using the formula V = 1/2 × a × b², and weigh the tumor using an electronic scale.
4. Fix the tumor tissues in 10% formalin solution followed by embedding in paraffin. Alternatively, snap-freeze the tumors in liquid nitrogen.
5. Excise the bones (hind limbs, vertebrae, and/or ribs) with metastatic lesions. Fix the specimen of each mouse in a 50 mL tube containing 20 mL of 10% formalin solution for 24 h after removing the skin and muscles, followed by decalcification for 14 days in 10% EDTA solution with frequent buffer change (every 3 days).
6. Embed the specimen in paraffin and section the samples for the routine histological examination¹⁶.

Wyniki

Bioluminescence imaging offers tremendous advantages in monitoring the metastatic lesion development for an intra-cardiac injection model. Soon after the cancer cell injection (within 24 h), bioluminescence imaging was used to visualize the cancer cells entering the general circulation (Figure 3A). Obvious bioluminescence signaling all over the body will be seen when the cancer cells are injected into the arterial circulation properly. Data from mice showing bioluminescence signals only at t...

Dyskusje

Intra-cardiac injection of human prostate cancer cells to generate bone metastasis is an ideal mouse model for exploring the functions and mechanisms of prostate cancer bone metastasis and evaluating the therapeutic efficacy. Studies have shown that bone damage most likely occurs in the proximal tibia and the distal femur¹⁷, which may be due to their high vascularization and metabolic activity.

Since bone metastasis is a frequently observed metastatic lesion in breast c...

Materiały

Name	Company	Catalog Number	Comments
1 mL syringes and needles	Shandong Weigao Group Medical Polymer Co., Ltd	20200411	The cells were injected into the ventricles of mice
Anesthesia machine	Shenzhen RWD Life Technology Co., Ltd	R500IP	Equipment for anesthetizing mice
Automatic cell counter	Shanghai Simo Biological Technology Co., Ltd	IC1000	For counting cells
BALB/c athymic mice	Shanghai SLAC Laboratory Animal Co, Ltd.	Male	6-8 week old, male mice
Bioluminescence imaging system	Shanghai Baitai Technology Co., Ltd	Vieworks	For tracking the tumor growth and pulmonary metastasis if the injected cells are labeled by luciferase
Centrifuge tube (15 mL, 50 mL)	Shanghai YueNian Biotechnology Co., Ltd	430790, Corning
EDTA solution	Wuhan Xavier Biotechnology Co., Ltd	G1105	For decalcification of bone tissure
F-12 medium	Shanghai YueNian Biotechnology Co., Ltd	21700075, GIBCO	Cell culture medium
Formalin solution	Shanghai YueNian Biotechnology Co., Ltd	BL539A	For fixing the specimen of each mouse
Isoflurane	Shenzhen RWD Life Technology Co., Ltd	VETEASY	For anesthesia
Lipofectamine 2000	Shanghai YueNian Biotechnology Co., Ltd	11668027, Thermo fisher	Plasmid transfection reagent
PC-3 cell line	Cell Bank of Chinese Academy of Sciences	TCHu 158	Prostate cancer cell line
Phosphate-buffered saline	Beyotime Biotechnology	ST447	Wash the human osteosarcoma cells
Trypsin (0.25%)	Shanghai YueNian Biotechnology Co., Ltd	25200056, Gibco	For detaching the cells
Vector (pLV-luciferase)	Shanghai YueNian Biotechnology Co., Ltd	VL3613	Plasmid for transfection
X-ray imaging system	Brook (Beijing) Technology Co., Ltd	FX PRO	For obtaining x-ray images to detect tumor growth
μCT80	Shenzhen Fraun Technology Service Co., Ltd	Scanco Medical AG,Switzerland	For detection of bone destruction. The mico-CT is equipped with 3DCalc, cone reconstruction,  and μCT Ray V3.4A model visualization software.